Neuronal cell death in Huntington's disease: a potential role for dopamine.
about
Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's diseaseStriatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicityMetabotropic glutamate receptors in the basal ganglia motor circuitMouse models of Huntington's disease and methodological considerations for therapeutic trials.Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription.Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.Tetrabenazine is neuroprotective in Huntington's disease mice.Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulationDifferential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity.Changes in striatal procedural memory coding correlate with learning deficits in a mouse model of Huntington diseaseIdentification and localization of a neuron-specific isoform of TAF1 in rat brain: implications for neuropathology of DYT3 dystoniaHuntington's Disease and Striatal Signaling.Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons.The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.Genetic or pharmacological blockade of noradrenaline synthesis enhances the neurochemical, behavioral, and neurotoxic effects of methamphetamine.Dopamine and glutamate in Huntington's disease: A balancing act.Molecular mechanisms and potential therapeutical targets in Huntington's disease.Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility.The role of dopamine in Huntington's disease.Revision of the classical dopamine D2 agonist pharmacophore based on an integrated medicinal chemistry, homology modelling and computational docking approach.Neuroprotection by saponins.Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.Neuroprotective effects of white tea against oxidative stress-induced toxicity in striatal cells.Plants-Derived Neuroprotective Agents: Cutting the Cycle of Cell Death through Multiple MechanismsAcute and long-term response of dopamine nigrostriatal synapses to a single, low-dose episode of 3-nitropropionic acid-mediated chemical hypoxia.Adverse effects of dopamine potentiation by long-term treatment with selegiline.Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum.Cyclosporine A attenuates 3-nitropropionic acid-induced Huntington-like symptoms in rats: possible nitric oxide mechanism.Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II.Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: relevance to Parkinson's disease.Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease.Improvement of mitochondrial function by paliperidone attenuates quinolinic acid-induced behavioural and neurochemical alterations in rats: implications in Huntington's disease.Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease.Involvement of dopamine receptors and beta-arrestin in metamphetamine-induced inclusions formation in PC12 cells.
P2860
Q27011417-671AE021-A165-46DE-BB19-08F21E8AD69AQ28239309-9D45EAB5-5D69-4482-B40A-B676A49ED0BDQ28280931-427EEB1E-FCA6-45B0-8C4F-038E67F3B253Q30481208-D65940A2-A810-4C6E-A7E4-87873C17B7A6Q33551416-9D5BEB47-173A-4D35-A6BE-6DE174FA9DEAQ33831774-1ACB243E-8577-42CC-A28F-15C09F717BB4Q33863426-0FD69F50-9619-4587-A0F1-C10F39E734ECQ33922831-9AE61808-7628-4F2D-96F6-465BA5C51788Q33931283-394E12FE-5DD5-479B-8339-8995E21321F3Q34654483-774F6A7E-9983-4155-8171-6A5ABC7BF46DQ35022005-70B6A2EE-DAD9-4B10-A183-E1A3B1900908Q35147361-559B92A5-625F-44F5-839F-F64F32D39311Q35286098-06D75C06-5537-4AD7-991C-19CE3F7B5A77Q35839434-81D30BD3-C435-47DB-803F-8728541EF928Q35978877-2864C175-D909-4E6E-A10A-5C40479492FDQ36045254-714746EA-A8A0-4A82-A30F-B098FD94749EQ37029888-946C1139-8A7D-4E5C-A706-7DE0AB36039DQ37734563-DE9B3B65-0CA7-4F7E-915D-FF1EFF7F3AF5Q37776087-CA8BD3DD-8D2E-432B-9428-07EA32E938CCQ38121068-DEE87DFA-0F24-404E-87AC-ECA13DB03292Q38223504-559331E7-32FA-497E-A8CA-F43CA72AE508Q38233283-7E2C8428-D074-4BA0-B80B-1293D9CEA6A2Q38269464-EB6B483F-42CA-4232-8125-DB2CF19BB62BQ38603960-22CBA2A7-77B5-4EE7-87E3-85C2118B2245Q38803243-EBABA183-539B-42EE-A332-C540A0F68496Q39519656-57CD1113-D045-4F18-BAF2-27ACFEB981EDQ41622472-568E35FC-3BA6-41EF-9294-75492F6C4C6FQ41841066-99E1FC74-4B91-47B9-B085-AE68DEF716D3Q42456123-1204A3F0-6260-4430-80EF-A1D4A934C924Q42713160-7E7CCA74-9488-4353-944F-1ACAFFCAC7EAQ43071425-BC8B3AF6-4C80-4E89-BF1F-161C6DC5F646Q43206399-0B8E6A83-534A-42E7-896A-E40FB1555B31Q43469689-C576371B-63A6-438D-B875-C3C25F20DBFAQ43516555-1A87EE98-C8EF-45F3-A644-E0A3B2E4279CQ43808667-8ED47121-FA09-42C7-842A-4031AD84803EQ44029787-527211CB-B4FC-4A03-B5E3-646FB3B0CDD2Q44553308-4D4C7C9B-1B7C-4571-A2C7-C4E97E72C196Q45298899-26411A77-1FC9-4F9D-9B4E-59FC9AC29D73Q45303900-EB390445-FC36-4BC3-9298-8871032CE2F5Q46759634-91FC939B-0208-4CBA-A78D-81039819A833
P2860
Neuronal cell death in Huntington's disease: a potential role for dopamine.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Neuronal cell death in Huntington's disease: a potential role for dopamine.
@ast
Neuronal cell death in Huntington's disease: a potential role for dopamine.
@en
type
label
Neuronal cell death in Huntington's disease: a potential role for dopamine.
@ast
Neuronal cell death in Huntington's disease: a potential role for dopamine.
@en
prefLabel
Neuronal cell death in Huntington's disease: a potential role for dopamine.
@ast
Neuronal cell death in Huntington's disease: a potential role for dopamine.
@en
P1476
Neuronal cell death in Huntington's disease: a potential role for dopamine.
@en
P2093
W F Maragos
P304
P356
10.1016/S0166-2236(00)01568-X
P577
2000-06-01T00:00:00Z